Coherus Oncology, Inc. (CHRS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US19249H1032
Coherus Oncology, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 42.17 m USD |
| Gross profit | 28.36 m USD |
| Operating income | -181.13 m USD |
| EBIT | 170.03 m USD |
| Net income | 168.02 m USD |
| Diluted EPS – continuing operations | 1.43 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Coherus Oncology, Inc.
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
More stocks
- Smith Douglas Homes Corp. (SDHC)
- Dual Co Ltd (016740.KS)
- Klingon Aerospace Inc (1529.TW)
- Feature Integration Technology Inc. (4951.TWO)
- Life Travel & Tourist Service Co., Ltd. (2745.TWO)
- DY Power Corp (210540.KS)
- Country Group Holdings Public Company Limited (CGH.BK)
- L&K Biomed Ltd. (156100.KQ)
- UNITED BANCORP INC /OH/ (UBCP)
- Dongyang E&P Inc (079960.KQ)
- SynAct Pharma AB (SYNACT.ST)
- International Integrated Systems, Inc. (6614.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.